File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.cotox.2023.100423
- Scopus: eid_2-s2.0-85170227187
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Gut microbiota: Impact on 5-fluorouracil efficacy and toxicity
Title | Gut microbiota: Impact on 5-fluorouracil efficacy and toxicity |
---|---|
Authors | |
Keywords | 5-Fluorouracil Butyric acid Chemotherapy Chemotherapy-induced toxicity Colorectal cancer Probiotic |
Issue Date | 6-Aug-2023 |
Publisher | Elsevier |
Citation | Current Opinion in Toxicology, 2023, v. 36 How to Cite? |
Abstract | Cancer is one of the most prevalent and deadly diseases worldwide. Despite medical advances, the survival rate of patients with cancer remains poor, and v many standard chemotherapeutic choices are associated with toxic side effects that substantially impair their quality of life. 5-Fluorouracil (5-Fu) is a widely used chemotherapeutic drug. Administration of 5-Fu is known to cause diarrhoea and intestinal mucositis. Butyrate is a short-chain fatty acid produced during the fermentation of dietary fibre by the gut microbiota. Butyrate may mitigate 5-Fu's toxic effect of mucositis. In addition, butyrate enhanced the efficiency of 5-Fu. However, the pungent odour of butyrate renders it unpalatable to patients. The administration of butyrate-producing bacteria is a preferable alternative for patients seeking the positive effects of butyrate without an unpleasant taste. Furthermore, butyrate-producing bacteria could provide beneficial effects beyond butyrate production, including the restoration of microbial dysbiosis and anti-inflammatory effects. In this review, we provide an overview of the current research on butyrate-producing bacteria, concentrating on their possible effects and defence mechanism against 5-Fu toxicity, which indicates their potential applicability as an adjuvant treatment for patients with cancer. |
Persistent Identifier | http://hdl.handle.net/10722/338192 |
ISSN |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lo, EKK | - |
dc.contributor.author | Leung, HKM | - |
dc.contributor.author | Zhang, F | - |
dc.contributor.author | El-Nezami, H | - |
dc.date.accessioned | 2024-03-11T10:26:57Z | - |
dc.date.available | 2024-03-11T10:26:57Z | - |
dc.date.issued | 2023-08-06 | - |
dc.identifier.citation | Current Opinion in Toxicology, 2023, v. 36 | - |
dc.identifier.issn | 2468-2934 | - |
dc.identifier.uri | http://hdl.handle.net/10722/338192 | - |
dc.description.abstract | Cancer is one of the most prevalent and deadly diseases worldwide. Despite medical advances, the survival rate of patients with cancer remains poor, and v many standard chemotherapeutic choices are associated with toxic side effects that substantially impair their quality of life. 5-Fluorouracil (5-Fu) is a widely used chemotherapeutic drug. Administration of 5-Fu is known to cause diarrhoea and intestinal mucositis. Butyrate is a short-chain fatty acid produced during the fermentation of dietary fibre by the gut microbiota. Butyrate may mitigate 5-Fu's toxic effect of mucositis. In addition, butyrate enhanced the efficiency of 5-Fu. However, the pungent odour of butyrate renders it unpalatable to patients. The administration of butyrate-producing bacteria is a preferable alternative for patients seeking the positive effects of butyrate without an unpleasant taste. Furthermore, butyrate-producing bacteria could provide beneficial effects beyond butyrate production, including the restoration of microbial dysbiosis and anti-inflammatory effects. In this review, we provide an overview of the current research on butyrate-producing bacteria, concentrating on their possible effects and defence mechanism against 5-Fu toxicity, which indicates their potential applicability as an adjuvant treatment for patients with cancer. | - |
dc.language | eng | - |
dc.publisher | Elsevier | - |
dc.relation.ispartof | Current Opinion in Toxicology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | 5-Fluorouracil | - |
dc.subject | Butyric acid | - |
dc.subject | Chemotherapy | - |
dc.subject | Chemotherapy-induced toxicity | - |
dc.subject | Colorectal cancer | - |
dc.subject | Probiotic | - |
dc.title | Gut microbiota: Impact on 5-fluorouracil efficacy and toxicity | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.cotox.2023.100423 | - |
dc.identifier.scopus | eid_2-s2.0-85170227187 | - |
dc.identifier.volume | 36 | - |
dc.identifier.eissn | 2468-2020 | - |
dc.identifier.issnl | 2468-2020 | - |